NCCN Guidelines are used by clinicians around the world as a standard resource for clinical decision-making. The NCCN Harmonized Guidelines™ are targeted regional resources created as part of a collaborative effort to combat the skyrocketing
cancer rates and unique circumstances of cancer care. They represent both the optimal care that resource-constrained areas aspire to provide and pragmatic approaches that could be used to improve the availability of effective treatment options.
Recommendations within the NCCN Harmonized Guidelines™ are represented as follows:
View available Harmonized Guidelines below or download the Virtual Library of NCCN Guidelines® App for your mobile device.
As part of a joint project with the African Cancer Coalition (ACC), American Cancer Society (ACS), the Clinton Health Access Initiative (CHAI), and IBM, NCCN and members of ACC adapted the NCCN Guidelines® and NCCN Framework for Resource Stratification of NCCN Guidelines (NCCN Framework™) to create the NCCN Harmonized Guidelines™ for Sub-Saharan Africa.
Acute Lymphoblastic Leukemia Version 1.2022
Acute Myeloid Leukemia Version 2.2022
Anal Carcinoma Version 2.2022
B-Cell Lymphomas Version 5.2022
Bladder Cancer Version 1.2023
Bone Cancer Version 2.2022
Breast Cancer Version 4.2021
Central Nervous System Cancers Version 2.2022
Cervical Cancer Version 1.2023
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2022
Chronic Myeloid Leukemia Version 1.2023
Colon Cancer Version 2.2022
Esophageal and Esophagogastric Junction Cancers Version 4.2020
Gastric Cancer Version 3.2020
Gastrointestinal Stromal Tumors Version 2.2022
Gestational Trophoblastic Neoplasia Version 1.2023
Head and Neck Cancers Version 1.2021
Hepatobiliary Cancers Version 3.2022
Hodgkin Lymphoma Version 2.2023
Kaposi Sarcoma Version 2.2021
Kidney Cancer Version 4.2023
Mesothelioma: Pleural Version 2.2021
Multiple Myeloma Version 3.2023
Neuroendocrine and Adrenal Tumors Version 1.2022
Non-Small Cell Lung Cancer Version 5.2022
Occult Primary Version 3.2023
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023
Pancreatic Adenocarcinoma Version 2.2022
Pediatric Acute Lymphoblastic Leukemia Version 2.2023
Pediatric Aggressive Mature B-Cell Lymphomas Version 3.2022
Pediatric Central Nervous System Cancers Version 2.2023
Penile Cancer Version 1.2023
Prostate Cancer Version 2.2021
Rectal Cancer Version 3.2022
Small Cell Lung Cancer Version 3.2023
Soft Tissue Sarcoma Version 2.2022
Testicular Cancer Version 1.2023
Thymomas and Thymic Carcinomas Version 1.2022
Thyroid Carcinoma Version 3.2022
Uterine Neoplasms Version 2.2023
Vulvar Cancer Version 1.2023
Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2023
Breast Cancer Screening and Diagnosis Version 1.2021
Colorectal Cancer Screening Version 3.2022
Prostate Cancer Early Detection Version 2.2021
Adult Cancer Pain Version 2.2021
Antiemesis Version 2.2020
Hematopoietic Growth Factors Version 2.2020
Palliative Care Version 2.2021
Prevention and Treatment of Cancer-Related Infections Version 1.2021
Smoking Cessation Version 2.2020
Survivorship Version 2.2020
Adolescent and Young Adult (AYA) Oncology Version 1.2021
Cancer in People with HIV Version 2.2021
As part of a joint project with the Caribbean Association for Oncology & Hematology (CAOH), NCCN and members of CAOH are adapting the NCCN Guidelines to create the NCCN Harmonized Guidelines™ for the Caribbean better reflect the diverse needs and resources throughout the Caribbean region.
Breast Cancer Version 1.2018
Cervical Cancer Version 1.2018
Colon Cancer Version 2.2018
Multiple Myeloma Version 4.2018
Non-Small Cell Lung Cancer Version 4.2018
Prostate Cancer Version 3.2018
Rectal Cancer Version 1.2018
For more information about NCCN collaborations to create the NCCN Harmonized Guidelines™, visit NCCN.org/news.
NCCN MAKES NO REPRESENTATIONS OR WARRANTIES CONCERNING THE NCCN CONTENT, THE NCCN GUIDELINES OR DERIVATIVE RESOURCES PROVIDED BY NCCN, ALL OF WHICH ARE PROVIDED "AS IS." NCCN DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. NCCN DOES NOT WARRANT THE ACCURACY, APPROPRIATENESS, APPLICABILITY OR COMPLETENESS OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY DERIVATIVE RESOURCES, NOR DOES NCCN MAKE ANY REPRESENTATIONS REGARDING THE USE OR RESULTS OF THE USE OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY SUCH DERIVATIVE RESOURCES.
NCCN EXPLICITLY DISCLAIMS THE APPROPRIATENESS OR APPLICABILITY OF THE NCCN CONTENT, THE NCCN GUIDELINES, AND ANY DERIVATIVE RESOURCES, OR THE USE OR APPLICATION OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY SUCH DERIVATIVE RESOURCES, TO ANY SPECIFIC PATIENT'S CARE OR TREATMENT. ANY CLINICIAN SEEKING TO APPLY OR CONSULT THE NCCN CONTENT, THE NCCN GUIDELINES AND/OR ANY DERIVATIVE RESOURCES IS EXPECTED TO USE INDEPENDENT MEDICAL JUDGMENT IN THE CONTEXT OF THE INDIVIDUAL CLINICAL CIRCUMSTANCES TO DETERMINE ANY PATIENT'S CARE OR TREATMENT.